Teladoc Health Inc (NYSE:TDOC) SVP Andrew Turitz Sells 9,158 Shares
Teladoc Health Inc (NYSE:TDOC) SVP Andrew Turitz sold 9,158 shares of Teladoc Health stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $62.27, for a total transaction of $570,268.66. Following the completion of the transaction, the senior vice president now directly owns 6,827 shares in the company, valued at approximately $425,117.29. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Andrew Turitz also recently made the following trade(s):
- On Monday, June 17th, Andrew Turitz sold 9,157 shares of Teladoc Health stock. The stock was sold at an average price of $60.05, for a total transaction of $549,877.85.
Shares of NYSE:TDOC traded up $3.30 on Wednesday, hitting $68.08. 1,341,586 shares of the company were exchanged, compared to its average volume of 1,347,052. The firm has a market capitalization of $4.66 billion, a P/E ratio of -47.28 and a beta of 1.35. The company has a current ratio of 7.56, a quick ratio of 7.56 and a debt-to-equity ratio of 0.43. Teladoc Health Inc has a 1-year low of $42.08 and a 1-year high of $89.05. The stock’s 50 day moving average price is $63.01 and its 200 day moving average price is $61.32.
A number of research firms recently commented on TDOC. Piper Jaffray Companies set a $87.00 target price on shares of Teladoc Health and gave the company a “buy” rating in a research report on Friday, August 16th. Bank of America started coverage on shares of Teladoc Health in a research note on Thursday, June 13th. They issued a “buy” rating and a $65.00 target price for the company. Oppenheimer set a $83.00 price target on shares of Teladoc Health and gave the stock a “buy” rating in a report on Friday, September 6th. Svb Leerink reaffirmed an “outperform” rating on shares of Teladoc Health in a research report on Thursday, August 1st. Finally, Craig Hallum increased their price objective on Teladoc Health from $70.00 to $80.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Three investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. Teladoc Health has an average rating of “Buy” and a consensus price target of $82.94.
A number of institutional investors have recently bought and sold shares of TDOC. Riversedge Advisors LLC acquired a new position in Teladoc Health during the second quarter valued at $223,000. River & Mercantile Asset Management LLP acquired a new stake in Teladoc Health during the 2nd quarter worth about $3,102,000. Griffin Asset Management Inc. purchased a new position in shares of Teladoc Health during the 2nd quarter valued at about $133,000. Kayne Anderson Rudnick Investment Management LLC raised its stake in shares of Teladoc Health by 39.6% during the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 133,757 shares of the health services provider’s stock valued at $8,883,000 after buying an additional 37,959 shares during the last quarter. Finally, Royal Bank of Canada raised its stake in shares of Teladoc Health by 40.5% during the 2nd quarter. Royal Bank of Canada now owns 276,005 shares of the health services provider’s stock valued at $18,329,000 after buying an additional 79,547 shares during the last quarter.
About Teladoc Health
Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
Further Reading: What does relative strength index mean?
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.